
Pfizer Inc (NYSE: PFE) has initiated a Phase 2/3 EPIC-PEDS trial to evaluate Paxlovid (nirmatrelvir and ritonavir tablets) in COVID-19 pediatric patients.
The trial will include non-hospitalized, symptomatic pediatric participants with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease. The Phase 2/3 trial has approximately 140 pediatric participants under 18 years of age.